Abstract: Provided in the present invention is the use of an enhancer named as 3C1 in the preparation of an enhancer for the interaction between FXR protein and Caspase 8 protein. The enhancer can promote the interaction between FXR protein and Caspase 8 protein, thereby inhibiting the recruitment of Caspase 8 to apoptosome and blocking its formation, inhibiting the cleavage and activation of Caspase 8, blocking signal transduction of apoptosis, and ultimately inhibiting cell apoptosis. Therefore, the enhancer can be used for preparing a drug for treating liver diseases characterized with hepatocyte apoptosis.

Abstract: Disclosed are a cell preservation solution, a preparation method for same, and applications thereof. The present disclosure specifically relates to a mesenchymal stem cell, NK cell, and CART cell preservation solution, a preparation method for same, and applications thereof. The contents of the components of the cell preservation solution are as follows: every 100 ml of the cell preservation solution contains 5-15 ml of human serum albumin, 80-90 ml of a compound electrolyte injection, 1-5 ml of a sulfate antioxidant-free compound amino acid injection, 0.01-1 g of L-glutamine, and 0.1-1 g of anhydrous glucose. The preservation solution of the present disclosure maintains a cell survival rate of no less than 80% for 144 h or more and an agglomeration rate of less than 12%, extends to the greatest extent the preservation time of a cell preparation, and implements the possibility for application at the national and even the global level.

Abstract: A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.

Abstract: The disclosure discloses a use of cyclic adenosine monophosphate (cAMP), derivative or prodrug thereof in preparation of drug for preventing and/or treating depression. Using the established model of depressed mice caused by social defeat stress, cAMP is intraperitoneally injected upon constructing the model or directly injected into the nucleus accumbens brain region of depressed mice after modeling, which can significantly improve the depression-like behavior of mice. The disclosure discloses the prevention and treatment effect of cAMP on depression, and provides a candidate drug with new mechanism for clinical prevention and treatment of depression.

Abstract: An azelaic acid gel, and a preparation method and an application thereof. The azelaic acid gel comprises the following components in percentage by weight: azelaic acid: 10-20%; salicylic acid: 0.5-2%; a polyacrylate cross-linked polymer-6: 1-3%; 1,3-propylene glycol: 60-74%; and the remaining part being water. The azelaic acid gel is used for preparing medicines for preventing or treating acnes.

Abstract: A composition containing SUMO inhibitor, and belongs to the technical field of medicine includes FXR agonist and SUMO inhibitor. In activated hepatic stellate cells, the FXR agonist does not have an effect in inhibiting the activation of hepatic stellate cells. After the FXR agonist and the SUMO inhibitor are compounded according to the present invention, the activation of hepatic stellate cells can also be inhibited for those cells under activated state. Of note, the hepatic stellate cells of an individual with hepatic fibrosis symptoms have been in an activated state, therefore a good anti-fibrotic effect cannot be achieved by using the FXR agonist alone.

Abstract: An azelaic acid gel, and a preparation method and an application thereof. The azelaic acid gel comprises the following components in percentage by weight: azelaic acid: 10-20%; salicylic acid: 0.5-2%; a polyacrylate cross-linked polymer-6: 1-3%; 1,3-propylene glycol: 60-74%; and the remaining part being water. The azelaic acid gel is used for preparing medicines for preventing or treating acnes.

Abstract: A method, node and system for controlling version in a distributed system. Wherein, the method includes: a management node is selected from each domain of the distributed system; one is selected as the synchronization source of the distributed system from all the management nodes, and all the management nodes synchronize the time with that of the synchronization source; all the management nodes control the time synchronization of the nodes in their own domain according to the synchronized time; the nodes of the distributed system control the version of the duplicate copy of the storage data according to the synchronized time. According to the technical scheme, it can be realized that the rough time synchronization of the distributed system, the expansibility and the practicability are improved, and the defects of the distributed system in the prior art, such as the poor expansibility and practicability, are solved.

Abstract: A method, node and system for controlling version in a distributed system. Wherein, the method includes: a management node is selected from each domain of the distributed system; one is selected as the synchronization source of the distributed system from all the management nodes, and all the management nodes synchronize the time with that of the synchronization source; all the management nodes control the time synchronization of the nodes in their own domain according to the synchronized time; the nodes of the distributed system control the version of the duplicate copy of the storage data according to the synchronized time. According to the technical scheme, it can be realized that the rough time synchronization of the distributed system, the expansibility and the practicability are improved, and the defects of the distributed system in the prior art, such as the poor expansibility and practicability, are solved.